Twelve questions patients ask before travelling to China

Most solid and haematological tumours have a corresponding protocol in China, but the real question is not "can it be treated" but "is travelling worthwhile". We first send pathology, imaging and prior treatment to a partner MDT; if China offers no clear advantage over your current option, we will tell you not to come.

Case review takes 3–5 business days; video consultations are usually arranged within 5–7 business days; in-person visits depend on the specialist's schedule, typically 1–3 weeks. Popular specialists (particle therapy, CAR-T centres) book further out — plan 3–4 weeks ahead.

It depends on whether local treatment still has value or whether China offers a specific drug or trial. If the goal is only a few weeks of survival gain and long-haul travel is required, we usually advise continuing locally and obtaining a second opinion remotely.

It varies widely by modality: conventional surgery and chemotherapy commonly RMB 80,000–200,000; proton therapy RMB 250,000–350,000; CAR-T drug cost RMB 1.0–1.3 million plus admission and complication management. We give a range first, and the hospital issues a formal estimate before treatment.

No. Hospital charges and our service fee are listed separately; the fee is published (see the pricing page), hospitals bill patients directly at official rates, and we take no share of hospital revenue.

It depends on your policy and the pre-authorization outcome. We work with 100+ international insurers and complete pre-authorization before treatment; direct billing depends on the insurer's approval, and if declined we help you claim reimbursement.

Usually an M-category visa for medical purposes or the corresponding medical stay endorsement, requiring a hospital invitation letter and appointment proof. Approval typically takes 5–10 business days, subject to the mission's requirements.

Yes, family members can apply for a corresponding visa. Inside the hospital our coordinators support Chinese-English-Russian (and other languages) during outpatient visits, admission and informed consent, and translate records and reports.

It varies: outpatient work-up plus surgery around 2–3 weeks; a chemotherapy cycle about 3 weeks; proton therapy 5–8 weeks; the full CAR-T pathway 6–10 weeks including post-infusion monitoring. The hospital gives the expected length of stay when the plan is confirmed.

Records are transferred only to the hospital you designate and only after written authorization, with encrypted transfer. We process data under PIPL and GDPR, never reuse it for marketing, and delete it at the end of the retention period.

At discharge you receive Chinese-English (or Russian) summaries, imaging and pathology; we help arrange remote follow-up, review of new results and continuity of medication.

Complications are managed by the treating hospital per clinical standards and billed as incurred; lack of response is reassessed by the hospital and the plan adjusted. We do not guarantee outcomes and cannot assume the hospital's medical responsibility, but we continue to assist with communication, referral and insurance claims.

Yes. A remote consultation is the right way to judge whether travelling is necessary and whether the current plan is sound. Most patients start there and decide afterwards.